General hospital psychiatry · 2026
Neuropsychiatric outcomes after deep brain stimulation for Parkinson's disease - Real-world data from a national movement disorders unit.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saw Lip Jie, Chan Lai Gwen, Li Wei, Ng Hwee Lan, Xu Zheyu, Tay Kay Yaw, Au Wing Lok, Wan Kai Rui, Neo Shermyn, Tan Louis Chew Seng
Аннотация
BACKGROUND: Effects of subthalamic nucleus Deep Brain Stimulation (DBS) for Parkinson's Disease on neuropsychiatric symptoms remains unclear, especially in the local context.
OBJECTIVES: To describe the frequencies, characteristics, and predictive factors of neuropsychiatric symptoms occurring before and up till 5 years after DBS for Parkinson's disease.
METHOD: Demographic and clinical data from a database of patients who underwent DBS for Parkinson's disease from April 2014 to April 2022 were retrospectively analysed. Neuropsychiatric symptoms were identified from medical records at four time-points: any time pre-DBS, only within 1 year pre-DBS, up to 1-year post-DBS (early-onset), and between 1 and 5 years post-DBS (later-onset). Outcomes included depressed mood, anxiety, cognitive decline, hallucinations, impulse control disorders and poor sleep.
RESULTS: DBS had an early beneficial effect on neuropsychiatric symptoms except for impulse control disorders (12.5% vs 10.4%, p = 1.0 and 10.4% vs 20.8%, p = 0.388) and cognitive decline (10.4% vs 12.5%, p = 1.0 and 10.4% vs 20.8%, p = 0.297). After 1 year, occurrences of neuropsychiatric outcomes approximated pre-DBS frequencies except for excess cognitive decline (52.1% vs 12.5%, p < 0.001 and 52.1% vs 20.8%, p = 0.007). Presence of recent pre-DBS mood symptoms predicted late-onset mood symptoms (adjusted odds ratio = 5.5, 95% CI 1.4-21.3, p = 0.014) and presence of recent pre-DBS hallucinations predicted early-onset post-DBS hallucinations (adjusted odds ratio = 36.4, 95% CI 1.4-962.8, p = 0.031).
CONCLUSION: There are likely at least short-term benefits on neuropsychiatric symptoms after bilateral subthalamic nucleus DBS for Parkinson's Disease.
OBJECTIVES: To describe the frequencies, characteristics, and predictive factors of neuropsychiatric symptoms occurring before and up till 5 years after DBS for Parkinson's disease.
METHOD: Demographic and clinical data from a database of patients who underwent DBS for Parkinson's disease from April 2014 to April 2022 were retrospectively analysed. Neuropsychiatric symptoms were identified from medical records at four time-points: any time pre-DBS, only within 1 year pre-DBS, up to 1-year post-DBS (early-onset), and between 1 and 5 years post-DBS (later-onset). Outcomes included depressed mood, anxiety, cognitive decline, hallucinations, impulse control disorders and poor sleep.
RESULTS: DBS had an early beneficial effect on neuropsychiatric symptoms except for impulse control disorders (12.5% vs 10.4%, p = 1.0 and 10.4% vs 20.8%, p = 0.388) and cognitive decline (10.4% vs 12.5%, p = 1.0 and 10.4% vs 20.8%, p = 0.297). After 1 year, occurrences of neuropsychiatric outcomes approximated pre-DBS frequencies except for excess cognitive decline (52.1% vs 12.5%, p < 0.001 and 52.1% vs 20.8%, p = 0.007). Presence of recent pre-DBS mood symptoms predicted late-onset mood symptoms (adjusted odds ratio = 5.5, 95% CI 1.4-21.3, p = 0.014) and presence of recent pre-DBS hallucinations predicted early-onset post-DBS hallucinations (adjusted odds ratio = 36.4, 95% CI 1.4-962.8, p = 0.031).
CONCLUSION: There are likely at least short-term benefits on neuropsychiatric symptoms after bilateral subthalamic nucleus DBS for Parkinson's Disease.